China Launches Phase 2 Study For Germany's mRNA Vaccine Candidate

BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd jointly announced on November 25, 2020, that their lead mRNA COVID-19 vaccine candidate BNT162b2 will be evaluated in a Phase 2 clinical trial in Taizhou and Lianshui, Jiangsu Province, China.

The recruitment of 960 healthy participants, aged between 18 and 85, to assess the safety and immunogenicity of the vaccine candidate and to support future Biologic License Application in China, is scheduled to start soon.

Dr. Aimin Hui, President of Global Research and Development and Chief Medical Officer of Fosun Pharma in China, said in a press release, “As an important part of global research and development, the Phase 2 clinical study with BNT162b2 in China will not only provide key data for the launch of the vaccine in China but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world.”